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SUMMARY:
Antiplatelet drugs are currently widely used in
primary and especially secondary prevention of cardio-
vascular events.
Dental management of patients on antiplatelet therapy
is still not clearly defined:  the discontinuation of antiplatelet
therapy increases the risk of thrombotic complications,
whereas uninterrupted antiplatelet therapy is assumed to
increase the bleeding complications after dental surgical
procedures.
The aim of this article is to review the main anti-
platelet drugs used for long-term oral antiplatelet therapy,
the laboratory methods for evaluating effectiveness of this
therapy, to identify the studies and guidelines available for
dental management of patients on antiplatelet drugs and to
summarize their conclusions and recommendations.
The methodology used through the research for the
literature review includes the following sources: Medscape,
Pubmed-Medline database, Science Direct, and EBSCO
host, the data base of Medical University Plovdiv and
specialised published books in general medicine and
dentistry.
The research proceeded by searching the next
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INTRODUCTION:
Antiplatelet therapy is wildly used in prevention of
risk of myocardial infarction, patients with atherosclerotic
vascular disease at high risk, treatment of acute coronary
syndrome, prior percutaneous coronary intervention,
coronary bypass, atrial fibrillation, stroke, in and treatment
of arterial and venous thrombosis.
Of concern to dental practitioners is the risk of
excessive bleeding during or after invasive dental
procedures. Although there have been strong warnings from
some authors and organizations that the risks from altering
dosage of or stopping antiplatelet drugs far outweigh any
benefit there remains a prevailing practice of discontinuation
of thetherapy before invasive dental procedures.
Antiplatelet medicines are shown in Table 1.
Table 1. Antiplatelet agents
COX Inhibitors of Prostaglandin Phosphodiester- Fibrinogen New class
Inchibitors ADP - mediated analogues ase inhibitors receptor P2Y12
activation of the antagonists inhibitor
GPIIb/IIIa (disynergists)
Acetylsalicylic Clopidigrel Alprostadil  Dipyridamole Abciximab Prasugrel
acid
Indobufen Ticlopidine Iloprost Eptifibatide
tromethamol
Ticagrelor Tirofiban
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Antiplatelet medicines used for long-term oral
therapy are:
COX Inchibitors
Acetylsalicylic acid
In 1899, a French chemist, Charles Frederic Gerhardt
was the first to isolate and prepare aspirin. The name aspirin
was derived from A "Acetyl" and Spirin from "Spirsaure",
an old German name for salicylic acid.
Aspirin has antiplatelet activity through its inhibition
of platelet aggregation.
Platelet function and the COX-1 enzyme are
irreversibly inhibited by aspirin lasting for up to 10 days
(i.e., the entire life of the platelet).
Aspirin is an approximately 150- to 200-fold more
potent inhibitor of the constitutive enzyme COX-1, which is
highly sensitive to low doses of aspirin (40-80 mg daily), than
COX-2. The antithrombotic properties of aspirin are effective
up to 320 mg daily. Accordingly, aspirin is maximally
effective as an antithrombotic agent at doses much lower than
those required for anti-inflammatory and analgesic functions.
In contrast, COX-2 is inhibited only by doses high enough
to have analgesic or anti-inflammatory effects.
Thus, low-dose aspirin (40 to 320 mg) inhibits platelet
aggregation, but does not interfere with PGI2 function or its
vasodilating effects. Indications: Unstable angina pectoris;
Acute myocardial infarction; Prevention of a repeat myocardial
infarction after an initial myocardial infarction (reinfarction
prophylaxis); Following surgery or other interventions in
arterial blood vessels (e.g after an aortocoronary venous bypass
(ACVB), in percutaneous transluminal cor-onary angioplasty
(PTCA); Prevention of transient alchemic attacks (TIA and
cerebral infraction following manifestation of the precursor
stages (e.g transient signs of paralysis in the face or arm muscles
or transient loss of vision) [1]
Indobufen
Indobufen inhibits platelet aggregation by reversibly
inhibiting the platelet cyclooxygenase enzyme thereby
suppressing thromboxane synthesis.
Oral indobufen is used in the secondary prevention
of thromboembolic complications in patients with or without
atrial fibrillation, in the prevention of graft occlusion after
coronary artery bypass graft (CABG) surgery and in the
treatment of intermittent claudication.
Indobufen may be an effective alternative for at risk
patients with nonrheumatic atrial fibrillation in whom
anticoagulant therapy is contraindicated or who are at higher
risk of bleeding.
Inhibitors of ADP-mediated activation of the
GPIIb/IIIa
Clopidigrel
Clopidogrel is an antiplatelet agent belonging to the
thienopyridine family.
Clopidogrel blocks the P2Y12 receptor on the
platelet cell membranes, inhibiting the ADP-induced platelet
aggregation. It is a pro-drug and needs to be metabolized
to its active metabolite by several hepatic cytochrome P450
isoenzymes.
Clopidogrel is indicated: as monotherapy for the
prevention of atherothrombotic events in patients suffering
myocardial infarction, ischaemic stroke or peripheral arterial
disease and in conjunction with aspirin in patients suffering
from acute coronary syndrome (ACS) for non-ST segment
elevation ACS (unstable angina or non-Q-wave myocardial
infarction) including patients undergoing a stent placement
following percutaneous coronary intervention (PCI) and ST
segment elevation acute myocardial infarction in medically
treated patients eligible for thrombolytic therapy.
Platelet inhibition by clopidogrel is both dose- and
time- dependent and patients are usually given a loading
dose of 300–600 mg and then maintained on 75 mg/day.
The duration of clopidogrel therapy varies according
to the indication:
- myocardial infarction - from a few days to less than
35 days,
- ischaemic stroke - from 7 days to less than 6
months,
- following the insertion of a bare metal stent (BMS)
- 4 to 12 weeks,
- following the insertion of a drug-eluting stent
(DES) - 6 to 12 months (local policies vary). [2, 3, 4]
Ticlopidine
Ticlopidine is an antiplatelet drug in the
thienopyridine family. Like clopidogrel, it is an adenosine
diphosphate (ADP) receptor inhibitor.
Action: Inhibits platelet aggregation by altering the
function of platelet membranes by blocking ADP receptors.
This prevents the conformational change of glycoprotein IIb/
IIIa which allows platelet binding to fibrinogen. Ticlopidine
prolongs bleeding time.
It is used in patients in whom aspirin is not tolerated,
or in whom dual antiplatelet therapy is desirable.
Ticagrelor
Ticagrelor is a new direct inhibitor of the platelet
P2Y12 receptor and therefore does not require metabolic
activation. Unlike thienopyridines, ticagrelor binds
reversibly to the P2Y12 receptor and at a site that is
independent of adenosine diphosphate (ADP) but still results
in suppression of ADP-induced platelet activation by
temporarily “locking” the receptor in an inactive state until
it dissociates. Ticagrelor has significantly faster onset and
offset of antiplatelet activity compared with clopidogrel in
subjects with stable coronary artery disease or acute
coronary syndromes. Ticagrelor is indicated for the
prevention of thrombotic events in patients with acute300 http://www.journal-imab-bg.org / J of IMAB. 2013, vol. 19, issue 2/
coronary syndrome or myocardial infarction with ST
elevation. The drug is combined with acetylsalicylic acid
unless the latter is contraindicated. [5, 7]
Phosphodiesterase inhibitors
Dipyridamole
Dipiridamole inhibits the cellular reuptake of
adenosine into platelets, red blood cells and endothelial cells
leading to increased extracellular concentrations of
adenosine.
Dipyridamole blocks the thromboxane syntheses as
well as the thromboxane receptor
In comparison with ASA which inhibits mainly
platelet aggregation, dipiridamole inhibits more platelet
adhesion then their aggregation.
Its action of phosphodiesterase is wholly reversible
and ceases about 24h after the drug is discontinued.
Used as an adjunct to oral anticoagulation for the
prophylaxis of thromboembolism associated with prosthetic
heart valves. Modified release dipyridamole preparations are
licensed for the secondary prevention of ischaemic stroke
and transient ischaemic attacks. [6]
New class P2Y12 inhibitor
Prasugrel – newest thienopyridine, which also
irreversibly binds to P2Y12-receptor with a rapid onset and
stronger inhibitory effect compared with clopidogrel.
Licensed for use with aspirin for the prevention of
atherothrombotic events in patients with acute coronary
syndrome (i.e. unstable angina, non-ST segment elevation
myocardial infarction or ST segment elevation myocardial
infarction undergoing primary or delayed PCI. [7, 8]
Laboratory tests for evaluation the degree of the
antiplatelet therapy
Most platelet function tests have been traditionally
utilized for the diagnosis and management of patients
presenting with bleeding problems rather than thrombosis.
However, as platelets are now implicated in the development
of atherothrombosis, new and existing platelet function tests
are increasingly being used for monitoring the efficacy of
the antiplatelet drugs used to treat these conditions. [2]
Bleeding time
Platelet function testing began with the application of
the in vivo bleeding time by Duke in 1910. The bleeding time
was still regarded as the most useful screening test of platelet
function until the early 1990’s.
Many studies have shown that a low dose of
Acetylsalicylic acid has an effect on bleeding time, but this
have no clinical significance.
Literature suggests overwhelmingly that prolonged
BTs do not translate into increased blood loss from surgery.
[9]
The platelet aggregation (impedance) test is a more
accurate screen than the cutaneous bleeding time test to
determine the adequacy of platelet responsiveness to
physiologic stimuli such as collagen, arachidonic acid, and
adenosine diphosphate.
However the predictive power of this test and other
platelet function tests for bleeding during or after invasive
dental procedures is not well documented.
At present, clinical and ex vivo platelet aggregation
measurements have not been particularly useful in guiding
the clinician as to the risks of bleeding following dental
extractions in patients who use antiplatelet drugs. [2, 10]
Platelet count is normally between 150 and 450 x
109/l blood. A normal platelet count, however, gives no
information about the platelet function.
Platelet function tests can be subdivided into platelet
adherence, aggregation or activation. Light transmission
aggregometry (LTA) was invented in the 1960’s and soon
revolutionized the diagnosis of primary haemostatic defects.
LTA is still regarded as the gold standard of platelet function
testing and by adding a panel of agonists to stirred platelets
it is possible to obtain a large amount of information about
many different aspects of platelet function.
However, it is not sufficiently sensitive to reliably
detect the effect of low-dose aspirin or clopidogrel. [10]
Partial thromboplastin time (APTT) and the
prothrombin time (PT) normalized using the international
normalized ratio (INR) also must be interpreted with caution
as they do not reflect the in vivo haemostatic response; the
interaction between the vessel wall, platelets, fibrinogen and
circulating coagulation factors. These tests have never been
validated for the prediction of haemorrhagic tendency and
are performed at 37 C°.
Number of new tests have been used to assess the
influence of antiplatelet drugs on platelets (PFA-100®,
VerifyNow® Aspirin, TEG platelet mapping®, Impact®, and
urinary Thromboxane, P2Y12 assay, TEG platelet mapping
system®, Impact, Plateletworks® flow cytometric analysis
of activation-dependent markers), but they are still not
widely available.
Formal randomized clinical trials are needed to
determine the extent to which abnormalities of common
laboratory tests of platelet function reflect an increased risk
of bleeding at the time of invasive dental procedures. [2, 10]
Therapy discontinuation and risk of adverse
cardiovascular events
Stopping antiplatelet agents prior to surgical
procedures may increase the risk of thromboembolic events.
A large meta-analysis involving 50,279 patients
taking aspirin for secondary prevention showed that their
risk of developing major cardiovascular events after aspirin
withdrawal was 3 times higher than in those who continued
aspirin therapy. [11]/ J of IMAB. 2013, vol. 19, issue 2/ http://www.journal-imab-bg.org 301
Use of low-dose aspirin in patients with
cardiovascular disease is estimated to prevent at least 10 to
20 fatal and nonfatal vascular events per every 1000 patients
taking the drug for 1 year who are at high risk (annual 4%-
8% risk) of serious vascular events. [1]
Collet et al. published 11 cases of coronary events
after aspirin cessation.
In a study of 1358 patients admitted for suspected
acute coronary syndrome, Collet et al. followed
prospectively 930 nonusers, 355 prior users, and 73 recent
withdrawers of oral antiplatelet agents to determine if prior
use or recent withdrawal influences the severity of acute
coronary syndrome (ACS) and the clinical outcomes of
death, myocardial infarction, and bleeding.
5% of the patients admitted with ACS had withdrawn
OAA within 3 weeks before admission. OAA was found to
be an independent predictor of both mortality and bleedings
at 30 days. It was concluded that prior users of OAA and
patients with recent interruption of OAA displayed worse
clinical outcomes than nonusers.
A study by Ferrari et al. evaluated the role of aspirin
withdrawal in a cohort of 1236 patients hospitalized for
ACS. A total of 51 (4.1%) of these patients discontinued
aspirin within 1 month of the ACS. 13 cases were withdrawn
from aspirin before a dental procedure. The mean delay
between aspirin withdrawal and the acute coronary event
was 1- 1.9 days (range 4-17 days).
Beving et al. found that rapid withdrawal of aspirin
may cause abnormally high levels of blood markers
reflecting an increase of thromboxane A2 which may have
possible
hazardous effects in patients with cardiovascular
disease. After aspirin discontinuation, the recovery of
cyclooxygenase activity may occur rapidly, with a
heterogeneous synthesis of thromboxane A2 by fresh
platelets.
They support the hypothesis that aspirin withdrawal
in coronary patients may represent a real risk for the
occurrence of a new coronary event.
In the Fischer et al. study of 8688 patients who
experienced first-time acute myocardial infarction, the risk
of acute myocardial infarction was 1.52 times greater for
subjects who stopped taking NSAIDs including aspirin from
1 to 29 days compared with nonusers.
Overall, the data supported the conclusion that among
ACS patients, the discontinuance of daily aspirin use
increases the risk for adverse clinical cardiovascular
outcomes during the first month after drug withdrawal.
Patients with stents are at high risk of thromboembolic
events and it has been found that the greatest risk for stent
thrombosis is premature discontinuation of clopidogrel.
It is therefore recommended that antiplatelet therapy
should not be stopped at any time without discussion with
an interventional cardiologist, but especially within the first
6 -12 months after DES insertion or the first 6-12 weeks
after BMS insertion. [12, 13]
Risks of bleeding associated with continuing
antiplatelet medications in the perioperative period
In every day practice owing to the threat of bleeding,
patients taking aspirin are often asked by their dentist or
surgeon to discontinue antiplatelet medications before a
procedure. This “recommendation” is often made without
consulting the cardiologist or the general practitioner who
prescribed the antiplatelet agents.
More than 20 studies and guidelines have been
investigated.
Lillis et al. reported 111 patients on clinically
indicated antiplatelet therapy: aspirin (n = 42), clopidogrel
(n = 36), and aspirin and clopidogrel (n = 42). After teeth
extractions they reported 66.7% occurrence of bleeding
within 30 minutes for patients on dual antiplatelet therapy,
2.6% for single antiplatelet and 0.4% in control subjects,
differences which were statistically significant. However, all
immediate bleeding complications were successfully
managed with local haemostatic measures. No patient
developed any late haemorrhage. They concluded that dental
extractions may be safely performed in patients receiving
single or dual antiplatelet therapy when appropriate local
haemostatic measures are taken, thus averting thrombotic
risk of temporary antiplatelet discontinuation.
In a study of Nooh et al. 102 subjects were on ASA
81 mg once a day for the previous 6 months. The control
group of 87 subjects did not use ASA. They concluded that
extraction of teeth in patients taking 81 mg of ASA did not
cause significant bleeding post-operatively. All post-
operative bleeding was controlled by using good local
measures.
Valerin et al. conducted a study with healthy patients
who presented for a single tooth extraction. They were
randomized to aspirin (325 mg/day) or placebo for two days
prior to extraction, and for two days following the
extraction. The cutaneous bleeding time was not statistically
different between the aspirin and placebo group. There was
no difference in duration of bleeding following extraction
between the aspirin and placebo groups, or with
intraoperative or postoperative bleeding outcomes.
Cardona-Tortajada et al. monitored 155 patients on
antiplatelet therapy who underwent dental extractions. 26
patients had minor bleeding complications which were
controlled by local haemostasis measurements.
They concluded that there is a clear relationship
between the numbers of extractions in the same session and
the subsequent haemorrhage and advice not extracting more
than 3 teeth at a time, and that these should either be
adjacent or correlative, not in different parts of the dental
arch. For molar teeth, no more than two adjacent teeth
should be extracted.302 http://www.journal-imab-bg.org / J of IMAB. 2013, vol. 19, issue 2/
Park MW et al. examined the safety of continuation
during dental extraction of dual or triple antiplatelet therapy
in 100 patients with DES. They found that no severe
bleeding or major cardiovascular events occurred after
dental extraction except for 2 cases (2%). These data suggest
that it may be feasible for patients with DES to continue
their antiplatelet therapy, even triple antiplatelet therapy, for
dental extraction. Although there remains a risk for bleeding
with this strategy, continuation of multiple antiplatelet
therapy may be relatively safe.
Krishan B. et al. included in a study 82 patients
requiring dental extractions of which 57 were on antiplatelet
therapy (aspirin). No patient had any episode of prolonged
or significant bleeding from the extraction sites. Local
hemostasis had been satisfactorily obtained in all cases with
the use of a pressure pack for 30 minutes. They also
concluded that routine dental extractions can be safely
performed in patients on long-term antiplatelet medication,
with no interruption or alteration of their medication.
Madan G.A. et al. conducted a study with 51 patients
on long-term therapy with acetylsalicylic acid 75 mg to 100
mg daily. Aspirin was not stopped for a single patient. There
was no postoperative bleeding in all cases. They concluded
that most minor oral surgery procedures can be carried out
safely without stopping long-term low-dose aspirin regimen.
Morimoto Y. et al. reported 87 cases, receiving
antiplatelet drugs. Teeth were extracted without reducing the
therapy, and oxidized cellulose was applied and suturing was
performed for local hemostasis. They also concluded that
sufficient haemostasis can be obtained in most cases of tooth
extraction and appropriate local haemostatic methods can be
successful when postoperative haemorrhage occurs. [14, 15,
16, 17, 18, 19, 20, 21]
Patients taking antiplatelet medications with the
following medical problems may be at higher risk of
prolonged bleeding following dental procedures: liver
impairment, and/or alcoholism, renal failure, thrombo-
cytopenia, haemophilia or other disorder of haemostasis,
currently receiving a course of cytotoxic medication, marrow
disorders, any concurrent medication affecting haemostasis
such as anticoagulants or anti-inflammatory drugs.
Prior to treating these patients consultation with
medical specialist (cardiologist) is recommended.  Referral
to a dental hospital or hospital based dental clinic may be
appropriate.  [22, 23, 24, 25]
Local haemostasis
A local anaesthetic containing a vasoconstrictor
should be administered by infiltration or by intraligamentary
injection wherever practical. Regional nerve blocks should
be avoided where possible. However, if there is no
alternative, the local anaesthetic should be administered
cautiously using an aspirating syringe.
The procedure should be as atraumatic as possible
and any bleeding should be managed using local measures.
Sockets should be gently packed with an absorbable
haemostatic dressing  e.g. oxidised cellulose, collagen
sponge or resorbable gelatin sponge then carefully sutured.
Following closure, pressure should be applied to the
socket(s) by using a gauze pad that the patient bites down
on for 15 to 30 minutes.
Fibrin sealants also can be used to reduce post-
operative hemorrhage in patients with a wide range of
degrees of surgical trauma. They stimulate the last stages of
the coagulation cascade, that is, the conversion of fibrinogen
to fibrin. [22, 25, 26, 27, 28]
Tranexamic acid impedes the proteolytic degradation
of fibrin by preventing the attachment of plasminogen and
plasmin. A 4.8% solution has been proven to be very
effective in reducing bleeding complications. [26]
Patients should be given clear instructions on the
management of the clot in the postoperative period and
advised:
· to look after the initial clot by resting while the
local anaesthetic wears off and the clot fully forms (2-3
hours),
· to avoid rinsing the mouth for 24 hours,
· not to suck hard or disturb the socket with the
tongue or any foreign object,
· to avoid hot liquids and hard foods for the rest of
the day,
· to avoid chewing on the affected side until it is clear
that a stable clot has formed. Care should then be taken to
avoid dislodging the clot,
· if bleeding continues or restarts, to apply pressure
over the socket using a folded clean handkerchief or gauze
pad for 20 minutes.
· If bleeding does not stop, the dentist should be
contacted; repacking and resuturing of the socket may be
required. [1, 4, 9, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]
Postoperative pain management:
Generally paracetamol is considered a safe over-the-
counter analgesic for patients taking antiplatelet medications
and it may be taken in normal doses if pain control is needed
and no contraindication exists.
NSAIDs should be used with caution in combination
with aspirin or clopidogrel. They can damage the lining of
the gastro-intestinal tract leading to bleeding that may be
worsened by aspirin or clopidogrel. [6]
Conclusions:
Long-standing dogma concerning the exaggerated
risk for bleeding during and after dental procedures results
in stopping antiplatelet medications before a procedure or
in unnecessary deferral of dental care.
This practice persists despite published
recommendations to the contrary./ J of IMAB. 2013, vol. 19, issue 2/ http://www.journal-imab-bg.org 303
Most studies and guidelines advise to not routinely
discontinue antiplatelet medication before dental surgery
because bleeding complications following dental procedures,
while inconvenient, do not carry the same risks as thrombo-
embolic complications.
According to the 2008 American College of Chest
Physicians (ACCP) and American Dental Association
Guidelines, aspirin may be discontinued preoperatively in
patients who use it in primary prevention and are not at a
high risk of cardiac events.
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